Research map: Lithium and GLP-1-based therapies in bipolar disorder: an emerging pharmacovigilance signal and monitoring considerations

Back to the article

Papers in this map

  1. Glucagon-Like Peptide 1 Induces Natriuresis in Healthy Subjects and in Insulin-Resistant Obese Men · Jean‐Pierre Gutzwiller · 2004 · 443 citations · Cited by this paper
  2. Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial · 2025 · Related
  3. Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men · Jeppe Skov · 2013 · 225 citations · Cited by this paper
  4. Unspoken needs: an essential perspective in the treatment of schizophrenia · 2026 · Related
  5. Clinical Relevance of Drug Interactions with Lithium · Patrick R. Finley · 1995 · 212 citations · Cited by this paper
  6. When antidepressants meet the gut microbiota: implications and challenges · 2024 · Related
  7. The burden of obesity among adults with bipolar disorder in the United States · Benjamin I. Goldstein · 2011 · 173 citations · Cited by this paper
  8. Innovations and challenges in antipsychotic treatments and external modulating factors · 2025 · Related
  9. Drug Interactions with Lithium: An Update · Patrick R. Finley · 2016 · 109 citations · Cited by this paper
  10. Brexpiprazole augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary retrospective observational study · 2025 · Related
  11. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management · Brent A. Hiramoto · 2024 · 92 citations · Cited by this paper
  12. The effects of lurasidone on five symptom domains and individual items in schizophrenia: Post-hoc analysis from Phase 3 study · 2025 · Related
  13. Lithium pharmacokinetics in the obese · Robert A. Reiss · 1994 · 58 citations · Cited by this paper
  14. Liraglutide in Obese or Overweight Individuals With Stable Bipolar Disorder · Susan L. McElroy · 2024 · 40 citations · Cited by this paper
  15. Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or Obesity · Piaopiao Li · 2025 · 40 citations · Cited by this paper
  16. Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers · Bettina Felicitas Winzeler · 2020 · 33 citations · Cited by this paper
  17. Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder · Majd Al‐Soleiti · 2025 · 11 citations · Cited by this paper
  18. The effect of delayed gastric emptying and absorption on pharmacokinetic parameters of lithium · Suleyman Eralp Bellibas · 1995 · 10 citations · Cited by this paper
  19. Semaglutide-Mediated Lithium Toxicity · Stevyndennis Onggo · 2025 · 7 citations · Cited by this paper
  20. Lithium toxicity following a change from semaglutide to tirzepatide for weight loss management · Jesse R. Burson · 2026 · 5 citations · Cited by this paper
  21. Potential protective role of GLP-1 receptor agonists for lithium-induced nephrotoxicity: a population-based observational study · Roger S. McIntyre · 2025 · 4 citations · Cited by this paper
  22. Question · Jonathan G. Leung · 2026 · 2 citations · Cited by this paper
  23. A Case of GLP-1 Receptor Agonist-Induced Lithium Neurotoxicity · Anuhya Kotta · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)